DBV Technologies S.A. (DBVT) vs Zevra Therapeutics (ZVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zevra Therapeutics (ZVRA) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 8.0% versus a loss of 46.6%. Over five years, ZVRA leads with a -1.5% price change compared with -18.0% for DBVT. Zevra Therapeutics is the larger company by market cap ($590.3 million vs $568.8 million), about 1.0 times the size.
Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | ZVRA |
|---|---|---|
| Share price | $9.05 | $9.94 |
| Market cap | $568.78M | $590.27M |
| 1-day change | -0.66% | -3.21% |
| YTD return | -52.79% | +10.94% |
| 1-year return | -46.61% | -8.01% |
| 5-year return | -18.03% | -1.49% |
| P/E ratio (TTM) | — | 10.80 |
| Forward P/E | — | 9.23 |
| EPS (TTM) | $-3.50 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $106.47M |
| Revenue growth (YoY) | +35.77% | +350.91% |
| Net income (latest FY) | $-146.95M | $83.23M |
| Gross margin | — | 84.52% |
| Operating margin | -2609.23% | -59.12% |
| Net margin | -2607.29% | 78.17% |
| 52-week high | $26.19 | $15.04 |
| 52-week low | $8.63 | $8.01 |
| Distance from 52-week high | -65.44% | -33.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +328.07% | +151.51% |
| Average volume | 350.73K | 1.07M |
| Shares outstanding | 62.85M | 59.38M |
| Employees | 170 | 61 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZVRA has outperformed DBVT by 38.6 percentage points over the past year.
- Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- Zevra Therapeutics grew revenue faster in its latest fiscal year (+350.91% vs +35.77%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
About Zevra Therapeutics
ZVRA stock →Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Healthcare · Biotechnology · 61 employees
DBVT vs ZVRA FAQ
Which is bigger, DBV Technologies S.A. or Zevra Therapeutics?
Zevra Therapeutics (ZVRA) is larger, with a market capitalization of $590.27M compared with $568.78M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or ZVRA?
ZVRA returned -8.01% over the past 12 months, compared with -46.61% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Zevra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.